|
|
Dare
Project
Introduction and Synopsis of the Dare Project
The Synergy Group led the development of a grant application to the
National Health and Medical Research Council, drawing on the experience
from the MiMA project in relation to MBCT, and submitted it for
consideration in the 2007 funding round. This application was successful
and work began on the project in 2007. Some details of the project follow:
Investigators:
Chief Investigators: Professors Graham Meadows, Fiona Judd,
Paul Martin, Zindel Segal, and Leon Piterman
Associate Investigators
Professors Michael Berk, Jayashri Kulkarni, Mark Oakley Browne and Alan
Shiell, Associate Professors David Clarke, Saji Damodaran, Damien Jolley
and Richard Newton, Dr Gavin Sullivan, Anthony Cichello, Ingrid Ozols and
Bob Sharples.
Project Staff Dr Fran Shawyer, Annette Graham,
Bernadette O'Grady, Debbie Lang.
Project Sites:
The DARE project is operating in the following regions of Victoria:
- Melbourne - CBD, inner and outer southern districts (Alfred
Hospital,
Melbourne; The Victoria Clinic, Prahran; Dandenong Hospital,
Dandenong)
- Geelong (The Geelong Clinic, St Albans Park)
- Mornington Peninsula (Frankston Hospital, Frankston).
Grant Synopsis:
Title
A Comparison of Mindfulness-Based Cognitive Therapy with Usual Treatment
plus Active Symptom Monitoring for Preventing Relapse in People Who Have
Had Recurrent Depression.
Background
Relapse rates for major depressive disorder (MDD) increase with
increased number of prior episodes so relapse prevention should be a
priority for people who have already suffered several episodes. Even with
guideline-based pharmacotherapy relapse is not uncommon so there is a need
for non-pharmacological approaches to relapse prevention. Mindfulness-Based
Cognitive Therapy (MBCT) combines cognitive therapy and mindfulness
meditation in an eight-week group instruction course delivered as
post-acute phase therapy for relapse prevention of major depression.
Randomised controlled trial (RCT) results from Canada and the United
Kingdom indicate that MBCT reduces relapse among recovered depressed
patients, particularly those with three or more prior depressive episodes,
but there is a need for further development of the empirical base for MBCT
including effectiveness studies in varied settings.
Aims
The primary aim of this project is to determine if MBCT when added to
existing treatment as usual plus regular monitoring of symptoms (depression
relapse – active monitoring – DRAM) is more effective than DRAM in
preventing depressive relapse in people who have had at least three prior
episodes of depression. The project will investigate the applicability and
effectiveness of MBCT as assessed in multiple and varied real world
settings.
The secondary aim of the project is to provide for a detailed examination
of the mechanisms by which this form of therapy may prevent depressive
relapse, with this examination structured in a way so as also to progress
the understanding of the clinical applicability of MBCT as a treatment for
relapse prevention in depression.
Research Plan
The main study will be a multi-site effectiveness study in the nature of a
pragmatic quantitative RCT with stratified groups including conditions of
MBCT and DRAM, all with usual medication encouraged and adherence
monitored. Enrolled participants will have had 3+depressive episodes and be
in remission from this disorder. Power considerations suggest recruiting at
least 344 people to interview. This will be assisted by the multi-site
design including mental health facilities from Barwon Health, Bayside
Health, Bendigo Health, Latrobe Valley Regional Hospital, Peninsula Health,
and Southern Health.
Time to relapse of major depressive disorder, time spent in relapse, and
levels of depressive symptomatology will be assessed by structured and
validated instruments, also psychiatric comorbidities, social functioning,
quality of life, health service utilisation and medication adherence.
Candidate mediators examined will include mindfulness, rumination,
neuroticism, openness to experience and time spent in meditation practice.
Measurement of incremental cost-utility of treatment will adopt a social
perspective with results subject to extensive probabilistic sensitivity
testing.
A parallel small exploratory grounded-theory based qualitative interview
study will seek to identify previously unconsidered relationships between
medication, mindfulness practice and clinical outcomes.
Outcomes and significance
This first major MBCT study from outside the therapy development group
will address the internationally important issue of transferability of the
technique, will enhance understandings of mechanisms of action and
importantly will establish effectiveness in combination with medication.
Cost utility analysis will enable specific policy recommendations for
Australia. Findings from this study would lead to MBCT having a high degree
of evidence-based support examining its use, so that it could be considered
as an intervention for which 'high', rather than 'moderate', levels of
evidence exist. Hence this study if positive would provide internationally
significant findings to support consideration of inclusion of this
treatment into guidelines for routine clinical management of the serious
and disabling problem of recurrent depression.
|